Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services... see more

NDAQ:VMD - Post Discussion

Viemed Healthcare Inc > Anticipating Q1 results
View:
Post by donmayne on Apr 27, 2022 9:45am

Anticipating Q1 results

Guidance given on March 7, 2022: (Note: Currency is all in US dollars)
“The Company expects to generate net revenues attributable to its core business of approximately $29.2 million to $30.2 million during the first quarter of 2022. In addition to its core business, the Company is continuing to pursue additional revenues related to the COVID-19 pandemic and estimates first quarter 2022 revenues of approximately $1.4 million to $1.8 million related to the COVID-19 pandemic. Total revenues for the first quarter of 2022 are estimated to be approximately $30.6 million to $32.0 million.”
The guidance for 2022 Q1 was made in early March, well through the quarter, so it is likely quite accurate. The midpoint of guidance suggests probable shrinkage in total revenue from the last quarter. but a shifting back to core revenue.  That midpoint shows growth of 4.5% in total revenue and 16.6% in core business revenue from Q1 last year.  
 
This was alluded to by Casey Hoyt in the March 8 conference call:
Moving onto some of the themes from the fourth quarter, we witnessed positive traction from our investments into our industry leasing service model during periods of COVID decline. Increased access to referral sources allowed us to demonstrate the evidence based benefits of our high touch, high tech delivery model of home respiratory care. As a result, our growth trends during these periods indicate an incredible opportunity for post COVID expansion. We are also seeing stabilization of several COVID related risks and uncertainties that have faced our industry over the course of this pandemic.
 
Guidance for Q2 will probably be the most important number to look for in the upcoming news release. I am hoping for core revenue guidance to reflect the historic growth rate of 30% (or perhaps higher) per annum on the core revenue and an elimination of pandemic related revenues. This would result in a midpoint guidance for Q2 at $31.7. 
 
In Casey Hoyt’s words:
As we begin to see a trend towards returning to our historical growth rate and traditional product lines, we are incredibly excited to continue to innovate and expand our services to meet the evolving needs of patients.
The Q1 results will be compared to Q1 2021 (year over year) and to q4 2021 (most recent quarter)
  • Q1 2021 Stats
  • Total Revenue: 28,416
  • Core Business revenue: 25,461
  • Covid related revenue: 2,995
  • Net Income: 1,684
  • Adjusted Ebita: 5,468
  • Cash balance: 31,097
  • Vent patients 7,733
·       Q4 2021 Stats
·       Total Revenue: 31,962
·       Core Business revenue: 28,947
·       Covid related revenue: 3,015
·       Net Income: 4,087
·       Adjusted Ebita: 9,549
·       Cash balance: 28,408
·       Vent patients 8,405
Negative in Q1: The first six weeks of 2022 were during the peak of Omicron and hospitals would have been overwhelmed and not responsive to VMD’s patient recruitment model. So patient growth would have stalled for the first half of the quarter, yet VMD has forged ahead in its hiring which will be a small drag on profit margins. 
 
Positive in Q1: The CPI reimbursement adjustment of 5% will flow to the bottom line.  Share price is still dismal so the egregious stock-based compensation will not be a factor.
 
Analyst earnings estimates for Q1 are low.  Given the revenue guidance, one would expect earnings to be in line with those of the prior quarter. Perhaps the analysts have taken a wait and see approach with their earnings estimates.  If the company can repeat the $0.10 eps in Q1, then the analysts will have to adjust their annual earnings estimates.  Perhaps RBC will also adjust the target price.  Key drivers for an expansion of the PE multiple will be the projected growth rate in per share earnings.
 
The stock repurchase plan for up to 5% of the shares would only be partially completed in the Q1 period. It will show a reduction in cash of about $2.5 million at the end of the quarter.
Comment by lastpick on Apr 27, 2022 3:53pm
Good summary Donmayne. Much appreciated!
Comment by besttobe on Apr 29, 2022 3:47pm
They will be lucky to meet their quidance as provided below, due to...covid restictions, inflation eating at their fix pricing, supply and labor constraints etc etc....Anyway, be prepared to take a big hit....when they miss...imo The Company expects to generate net revenues attributable to its core business of approximately $29.2 million to $30.2 million during the first quarter of 2022. In ...more  
Comment by LongTerm3 on May 02, 2022 11:42am
The last conference call was March 8th, which is two months into the quarter. It seemed to be good. I doubt they will mss earnings. I'm really not sure what your objective is in bashing a company that you don't hold shares in.
Comment by Peanuts3 on May 03, 2022 8:10pm
Where is this stupid guy ???
Comment by besttobe on May 04, 2022 7:41am
They were lucky to meet their revenue guidance because of extra covid sales. They also missed on EPS because ebitda margins declined quite significantly. Inflation....supply change constraints and labor shortage....the cause..IMO? Hmmm..they have some explaining to do. IMO GLTA
Comment by LongTerm3 on May 04, 2022 8:13am
The top line revenue is going up.  Are you a paid basher? That is the main question regarding Viemed.  Your math is going the wrong way, as compared to Viemed.
Comment by Trytobelong on May 04, 2022 9:13am
Hey Longterm: have you seen positive things about VMD or QIPT from his mouth ?
Comment by LongTerm3 on May 04, 2022 9:22am
Never, he has to be getting paid to do this, or he has nothing else to do with his life. I'm very happy with the results and guidance for the next quarter.
Comment by besttobe on May 04, 2022 9:46am
Why is there anything positive to say.....Have you seen anything positive in the S/P of both Quipt and VMD? 
Comment by Trytobelong on May 04, 2022 9:53am
oupsss... investors are liking results more than you Bestobe... lollllll
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities